Literature DB >> 10617688

Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels.

C C Kuo1, R C Huang, B S Lou.   

Abstract

Diphenhydramine is an H1 histamine receptor antagonist, yet it also has a clinically useful local anesthetic effect. We found that diphenhydramine inhibits the neuronal Na(+) current, and the inhibition is stronger with more positive holding potentials. The dissociation constant between diphenhydramine and the inactivated Na(+) channel is approximately 10 microM, whereas the dissociation constant between diphenhydramine and the resting channel is more than 300 microM. The local anesthetic effect of diphenhydramine thus is ascribable to inhibition of Na(+) current by selective binding of the drug to the inactivated channels. Most interestingly, many other compounds, such as the anti-inflammatory drug diclofenac, the anticonvulsant drug phenytoin, the antidepressant drug imipramine, and the anticholinergic drug benztropine, have similar effects on neuronal Na(+) current. There is no apparent common motif in the chemical structure of these compounds, except that they all contain two phenyl groups. Molecular modeling further shows that the two benzene rings in all these drugs have very similar spatial orientations (stem bond angle, approximately 110 degrees; center-center distance, approximately 5 A). In contrast, the two phenyl groups in phenylbutazone, a drug that has only a slight effect on Na(+) current, are oriented in quite a different way. These findings strongly suggest that the two phenyl groups are the key ligands interacting with the channel. Because the binding counterpart of a benzene ring usually is also a benzene ring, some aromatic side chain groups of the Na(+) channel presumably are realigned during the gating process to make the very different affinity to the aforementioned drugs between the inactivated and the resting channels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617688

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  17 in total

1.  An inactivation stabilizer of the Na+ channel acts as an opportunistic pore blocker modulated by external Na+.

Authors:  Ya-Chin Yang; Chung-Chin Kuo
Journal:  J Gen Physiol       Date:  2005-04-11       Impact factor: 4.086

2.  Aconitum and Delphinium sp. alkaloids as antagonist modulators of voltage-gated Na+ channels. AM1/DFT electronic structure investigations and QSAR studies.

Authors:  Malakhat A Turabekova; Bakhtiyor F Rasulev; Mikhail G Levkovich; Nasrulla D Abdullaev; Jerzy Leszczynski
Journal:  Comput Biol Chem       Date:  2007-10-24       Impact factor: 2.877

3.  A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile.

Authors:  Paul W Lenkowski; Timothy W Batts; Misty D Smith; Seong-Hoon Ko; Paulianda J Jones; Catherine H Taylor; Ashley K McCusker; Gary C Davis; Hali A Hartmann; H Steve White; Milton L Brown; Manoj K Patel
Journal:  Neuropharmacology       Date:  2006-12-14       Impact factor: 5.250

4.  Case files of the medical toxicology fellowship at Drexel University. Rhabdomyolysis and compartment syndrome following acute diphenhydramine overdose.

Authors:  David Vearrier; John A Curtis
Journal:  J Med Toxicol       Date:  2011-09

5.  Voltage-dependent modulation of TRPA1 currents by diphenhydramine.

Authors:  Xianfeng Shen; Qiaochu Wang; Yakang Lin; Koti Sreekrishna; Zhiyuan Jian; Michael X Zhu; Jinbin Tian
Journal:  Cell Calcium       Date:  2020-06-21       Impact factor: 6.817

6.  Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.

Authors:  Elisabetta Poluzzi; I Diemberger; M De Ridder; A Koci; M Clo; A Oteri; S Pecchioli; I Bezemer; T Schink; S Pilgaard Ulrichsen; G Boriani; M C J Sturkenboom; F De Ponti; G Trifirò
Journal:  Eur J Clin Pharmacol       Date:  2017-08-22       Impact factor: 2.953

7.  V102862 (Co 102862): a potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels.

Authors:  Victor I Ilyin; Dianne D Hodges; Edward R Whittemore; Richard B Carter; Sui Xiong Cai; Richard M Woodward
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

8.  Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.

Authors:  Annamaria De Luca; Sophie Talon; Michela De Bellis; Jean-François Desaphy; Carlo Franchini; Giovanni Lentini; Alessia Catalano; Filomena Corbo; Vincenzo Tortorella; Diana Conte-Camerino
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

Review 9.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).

Authors:  Pieter G Postema; Christian Wolpert; Ahmad S Amin; Vincent Probst; Martin Borggrefe; Dan M Roden; Silvia G Priori; Hanno L Tan; Masayasu Hiraoka; Josep Brugada; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2009-07-08       Impact factor: 6.343

10.  The external pore loop interacts with S6 and S3-S4 linker in domain 4 to assume an essential role in gating control and anticonvulsant action in the Na(+) channel.

Authors:  Ya-Chin Yang; Jui-Yi Hsieh; Chung-Chin Kuo
Journal:  J Gen Physiol       Date:  2009-08       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.